Advent to invest $175 million in Felix Pharma to acquire minority stake

While Felix Pharmaceuticals achieved its first U.S. FDA approval in 2020, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline.

from Industry News, Company News, Manufacturing News, Service Sector | The Hindu https://ift.tt/tyJDW2S

Comments

Post a Comment

Popular posts from this blog

Continuous Glucose Monitoring (CGM) Market in the US, 2025

Image
  United States Continuous Glucose Monitoring (CGM) Market Size and Trends The United States  Continuous Glucose Monitoring  (CGM) market size was valued at USD 3.7 billion in 2024 and is projected to hit around USD 8.4 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025 to 2033. United States Continuous Glucose Monitoring (CGM) Market Growth Drivers One of the primary drivers fuelling the growth of the  CGM market  in the United States is the rising prevalence of diabetes. According to recent statistics, millions of  Americans  are diagnosed with diabetes each year, leading to a growing need for effective monitoring solutions. Additionally, increasing health awareness and technological advancements in  sensor technology  have encouraged more patients and healthcare providers to turn to CGM systems. United States Continuous Glucose Monitoring (CGM) Market Synopsis This  market report  is based on an inclu...
Read more